News

Filter

Current filters:

OncologyMerck & Co

1 to 9 of 94 results

Bristol-Myers will lead immuno-oncology market in 2022, say analysts

Bristol-Myers will lead immuno-oncology market in 2022, say analysts

04-03-2015

Analysts at Morningstar Equity Research see significantly more opportunity than the overall market for…

AstraZenecaBiotechnologyBristol-Myers SquibbMarkets & MarketingMerck & CoOncologyOpdivoResearchRoche

Targeted lung cancer therapies supplanting conventional drugs; report

03-03-2015

Although lung cancer is the third most prevalent cancer type in the world, there are only 18 drugs in…

AstraZenecaBristol-Myers SquibbEli LillyMarkets & MarketingMerck & ConecitumumabOncologyOpdivoPharmaceuticalResearchRoche

Bristol-Myers Squibb gives full responsibility for Erbitux in Japan to Merck

Bristol-Myers Squibb gives full responsibility for Erbitux in Japan to Merck

13-02-2015

German pharmaceuticals and chemicals major Merck KGaA is to end the co-promotion of Erbitux (cetuximab)…

Bristol-Myers SquibbErbituxJapanLicensingMerck & CoOncologyPharmaceutical

Merck & Co updates on plans to accelerate new drug submissions and future growth

Merck & Co updates on plans to accelerate new drug submissions and future growth

13-01-2015

US pharma giant Merck & Co has reported on the ongoing execution of its multi-year, strategic initiative…

Anti-viralsgrazoprevir/elbasvirKeytrudaMerck & CoOncologyPharmaceuticalRegulationResearchUSA

FDA approves Bristol-Myers Squibb’s Opdivo for advanced melanoma

FDA approves Bristol-Myers Squibb’s Opdivo for advanced melanoma

23-12-2014

The US Food and Drug Administration yesterday granted accelerated approval to US pharma major Bristol-Myers…

Bristol-Myers SquibbKeytrudaMerck & CoOncologyOpdivoPharmaceuticalRegulationUSA

Merck & Co in up to $375 million deal to acquire OncoEthix

Merck & Co in up to $375 million deal to acquire OncoEthix

19-12-2014

US pharma giant Merck & Co said yesterday that it has acquired, through a subsidiary, Swiss-based privately…

BiotechnologyMerck & CoMergers & AcquisitionsOncoEthixOncologyOTX015

Merck presents early data on Keytruda in advanced triple-negative breast cancer

Merck presents early data on Keytruda in advanced triple-negative breast cancer

11-12-2014

Pharma giant Merck & Co says Keytruda (pembrolizumab) has achieved an overall response rate of 18.5%…

KeytrudaMerck & CoOncologyPharmaceuticalResearchUSA

Merck’s new Gardasil 9 gains backing from US FDA

Merck’s new Gardasil 9 gains backing from US FDA

11-12-2014

The US Food and Drug Administration yesterday approved pharma giant Merck & Co’s Gardasil 9-valent…

Gardasil 9Merck & CoOncologyPharmaceuticalRegulationUSAVaccines

1 to 9 of 94 results

COMPANY SPOTLIGHT

Menarini

Back to top